Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the sanction of a supplemental Biologics License Application (sBLA) via the U.S. Food and Drug Administration (FDA) enclosed by support of TYSABRĮ̉ (natalizumab). TYSABRI be presently voted for for inducing and maintain clinical riposte and remission in mature patients hard by fairly [...]
Entries from January 2009
FDA Approves TysabriÃâ For The Treatment Of Moderate-To-Severe Crohn’s Disease
January 24th, 2009 · No Comments
Tags: 1
